MeiraGTx Holdings plc, a clinical-stage gene therapy company, focused on developing treatments for patients living with serious illnesses. The company is headquartered in New York, New York.
| Revenue (TTM) | $79.76M |
| Gross Profit (TTM) | $76.09M |
| EBITDA | $-92.72M |
| Operating Margin | -13931.00% |
| Return on Equity | -368.20% |
| Return on Assets | -28.10% |
| Revenue/Share (TTM) | $0.98 |
| Book Value | $-0.71 |
| Price-to-Book | 228.30 |
| Price-to-Sales (TTM) | 17.02 |
| EV/Revenue | 16.36 |
| EV/EBITDA | -3.29 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -84.80% |
| Shares Outstanding | $92.61M |
| Float | $52.26M |
| % Insiders | 17.12% |
| % Institutions | 60.91% |
Volatility is currently expanding
MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced that it has entered into an agreement with Oberland Capital Management LLC (Oberland Capital) for an investment of up to $400 million in the Company, including up to $375 million in non-dilutive capital for capped royalty payments on certain products and up to $25 million in equity.
MeiraGTx is evolving into a late-stage, manufacturing-enabled genetic medicine company with multiple near-term regulatory catalysts. MGTX's robust manufacturing infrastructure and targeted therapies, such as Bota-vec and AAV2-hAQP1, position it for commercial inflection without mass-market commercialization burdens. Recent equity raise and anticipated milestone payments extend MGTX's cash runway through 2H 2028, supporting execution of late-stage programs.
MeiraGTx Holdings plc (MGTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
MeiraGTx Holdings plc (MGTX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced that the Compensation Committee of the Company's Board of Directors approved equity awards to Penny Fleck in connection with her employment with the Company as Chief Development Officer. The equity awards were granted as an inducement material to the new employee entering employment with MeiraGTx in accordance with Nasdaq Listing Rule 5635(c)(4).
MeiraGTx Holdings PLC (MGTX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.51 per share a year ago.
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia Entered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) Strengthened balance sheet with $100 million financing LONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2026, and provided a corporate update. “Our achievements in the first few months of 2026 have materially strengthened MeiraGTx – we are now in a position to file for potential approval and launch two wholly-owned therapies in the next 2 years,” said Alexandria Forbes, Ph.D.
MeiraGTx (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MeiraGTx (MGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
